Cargando…

Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient

This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was r...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaral, Leonard, Molnar, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816647/
https://www.ncbi.nlm.nih.gov/pubmed/24280703
http://dx.doi.org/10.3390/ph5091021
_version_ 1782477965853982720
author Amaral, Leonard
Molnar, Joseph
author_facet Amaral, Leonard
Molnar, Joseph
author_sort Amaral, Leonard
collection PubMed
description This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries.
format Online
Article
Text
id pubmed-3816647
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38166472013-11-14 Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient Amaral, Leonard Molnar, Joseph Pharmaceuticals (Basel) Review This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries. MDPI 2012-09-17 /pmc/articles/PMC3816647/ /pubmed/24280703 http://dx.doi.org/10.3390/ph5091021 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Amaral, Leonard
Molnar, Joseph
Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title_full Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title_fullStr Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title_full_unstemmed Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title_short Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
title_sort why and how the old neuroleptic thioridazine cures the xdr-tb patient
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816647/
https://www.ncbi.nlm.nih.gov/pubmed/24280703
http://dx.doi.org/10.3390/ph5091021
work_keys_str_mv AT amaralleonard whyandhowtheoldneurolepticthioridazinecuresthexdrtbpatient
AT molnarjoseph whyandhowtheoldneurolepticthioridazinecuresthexdrtbpatient